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Abstract: The most appropriate strategy and timing for surgery in infective endocarditis (IE) remains 
an argument of debate. Despite some authors promote the adoption of an early surgical approach (within 
48 hours) to limit mortality and complications, no robust randomized trials are available on this argument 
and the evidence on this subject remain at the “expert opinion” level. Additionally, the different messages 
promulgated by the American and European guidelines contributed to fuel confusion regarding the 
relative priority of the surgical over medical therapy in IE. The European Society of Cardiology (ESC) 
guidelines individuates three level of urgency: emergency surgery, to be performed within 24 hours; urgent 
surgery, recommended within a few days; elective surgery to be performed after 1–2 weeks of antibiotic 
therapy. Urgent surgery is recommended for most cases of IE. In the American Heart Association (AHA)’s 
guidelines define early surgery as “during the initial hospitalization and before completion of a full course 
of antibiotics.” Some of the available evidences showed that are no proven benefits in delaying surgery if a 
definite diagnosis of IE has been established. However, this argument is controversial across the literature 
and several factors including the center specific experience can play a role in decision-making. In this review 
the latest evidences on IE clinical and surgical characteristics along with the current studies on the adoption 
of an early surgical approach are analyzed to clarify whether enough evidence is available to inform an update 
of the guidelines. 
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Introduction 
Despite the progress achieved in recent years for the treatment 
of infectious endocarditis in both the medical and surgical 
fields, this clinical-pathological entity remains a serious disease 
carrying a significant risk of death and morbidity (1-4). The 
use of surgery has gained momentum in the treatment of 
infectious endocarditis and it is expanding. However, current 
guidelines are cautious in supporting broad application of 
surgery in complicated left-sided infectious endocarditis 
(2,5,6). Although early surgery is highly recommended in 
patients with infective endocarditis (IE) who present with signs 
of congestive heart failure (3-6), the indications for surgery 
to prevent systemic embolism remain undefined (7-9). The 
main concern is for patients with large vegetation and a high 
risk of embolism (4,10). In these patients’ early surgery with 
complete excision of infected tissue and valve repair have 
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been achieved in high-volume centers with low mortality 
suggesting the benefit of early surgical management (1,4-6,11). 
However, concerns remain regarding the technical challenge 
of performing surgery in the presence of active infection and 
inflammatory response (1,12).
The 2014 American College of Cardiology-American 
Heart Association (ACC-AHA) guidelines (13) recommend 
the use of early surgery as class IIa indication only in 
patients who have recurrent emboli and persistent 
vegetation. Instead, the guidelines of the European Society 
of Cardiology (ESC) (6) recommend the use of early 
surgery as class IIb indication in patients who have isolated 
and very large vegetations (>15 mm in diameter). The non-
univocal recommendation from the two Society guidelines 
and the lack of randomized studies related to the presence 
of ethical, logistical, and financial constraints, impede to 
clarify the best indications for surgery and its timing (6).
The best timing for surgery is even more important in 
patients with prosthetic valve endocarditis (PVE), which 
present in 3% to 6% of the patients within 5 years of surgery 
and is associated with significant morbidity and mortality 
(14-17). Surgical debridement and valve replacement are 
recommended by consensus guidelines (6,14) in patients 
with IE who experience complications such as valve 
dysfunction, dehiscence, heart failure, cardiac abscess, 
or persistent bacteremia. However, these guidelines rely 
largely on expert opinion and limited observational data (18). 
There are several studies that have compared survival 
between patients undergoing surgery and medical therapy 
for PVE but they have reported conflicting results 
(15,18-25). Furthermore, their retrospective nature, low 
sample size and risk for treatment allocation bias profoundly 
limit the power of these studies. 
The only randomized evidence comparing the use of 
early surgery to medical treatment enrolled only a small 
number of patients with native valve endocarditis due to 
the streptococcal pathogen (26). No randomized studies on 
PVE are currently available. 
The objective of this review is to evaluate whether an 
answer can be given on the question regarding the best 
strategy to be adopted in the early treatment of IE. 
We present the following article in accordance with the 
Narrative Review reporting checklist (available at http://
dx.doi.org/10.21037/atm-20-3880).
Methods
A search of the PubMed database using the terms 
“endocarditis”, “left side endocarditis “, “right side 
endocarditis”, “aortic valve endocarditis”, “mitral valve 
endocarditis”, “tricuspid valve endocarditis”, “heart valve 
prosthesis”, “allograft”, “autograft”, “cardiac valve surgery”, 
“early surgery”, “delayed surgery”, was coordinated. 
Qualified abstracts were independently reviewed by two 
investigators and the related articles were evaluated. 
References for all selected studies were cross checked. 
Data from randomized controlled trials (RCT), unmatched 
observational series, observational series corresponding to 




Patients with sepsis of unknown origin or fever in the 
presence of risk factors should always trigger the suspicion 
of IE. They should have a careful assessment of symptoms 
and should undergo a clinical and microbiological 
investigation followed by transthoracic echocardiography 
to assess the mechanism and severity of heart valve 
infection, as well as left ventricular size and function. The 
manifestations of sepsis can fluctuate from general malaise 
to shock because they are influenced both by the virulence 
of the pathogen and by the host’s immune response (27,28). 
Usually Gram-positive Cocci of the staphylococcus, 
streptococcus and enterococcus species are responsible for 
80–90% of infectious endocarditis. S aureus is the most 
frequently isolated pathogen in infectious endocarditis in 
high-income countries with a reported percentage of 30% 
of cases (29,30). In particular, a microbiological diagnosis 
of S aureus bacteraemia is associated with infectious 
endocarditis in 25–30% of cases and all patients must be 
received echocardiography (31,32).
Patients with IE who present in a critical phase should be 
judiciously evaluated for risk of embolism and hemodynamic 
deterioration towards heart failure. Risk factors as 
underlying hemodialysis or addiction to the intravenous 
drug should be considered (33). The infection can be 
localized on the native and prosthetic valves, and patients 
might be asymptomatic without clinical cardiovascular 
deterioration for few days after infection (Figure 1).
Hemodynamic decompensation and heart failure
The most common indication to perform early operation 
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Figure 1 Pathway for Management of IE. ACC/AHA, American College of Cardiology/American Heart association; CAD, coronary artery 
disease; EROA, effective regurgitant orifice area; ESC, European Society of Cardiologists; FA, atrial fibrillation; IE, infective endocarditis; 
LV, left ventricle; LA, left atrium; PASP, pulmonary artery systolic pressure; TTE , transthoracic echocardiography; RF, regurgitant fraction; 
Rvol, regurgitant volume. 
in patients with IE is the development of heart failure. 
Increasing severity of valve regurgitation, even among 
asymptomatic patients, imposes a volume load on the left 
ventricle, which, if sustained over time, results in ventricular 
dilatation, hypertrophy, neurohormonal activation, and 
heart failure. In addition, in presence of a mitral valve 
endocarditis elevation in the mean left atrial pressure leads 
to left atrial enlargement, atrial fibrillation, pulmonary 
congestion, and pulmonary hypertension. Valve obstruction 
is another factor determining hemodynamic instability 
and heart failure. Evidence from numerous cohort studies 
revealed that the results were nefarious in patients who had 
not received emergency surgery because of the progression 
to pulmonary edema or cardiogenic shock (4,34-36). 
The presence of a large vegetation that compromises the 
functionality of the entire valve—rarely only a single leaflet 
is involved—can have a faster deterioration with progression 
of hemodynamic instability. These patients have valves 
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Figure 2 Clinical Algorithm for the Management of IE. CT, computed tomography; GDMT, guide direct medical therapy; MRI, magnetic; 
PET/CT, positron emission; TEE, transoesophageal echocardiography TTE, transthoracic echocardiography; SPECT, single-photon 
emission computed tomography. 
seriously affected by infection with a cauliflower-like lesion 
(4,37). In patients with limited degree of valve regurgitation 
valve regurgitation surgery can be deferred surgery after a 
period of stabilization with antibiotic therapy, but there are 
no randomized controlled clinical trials that satisfactorily 
guide clinical practice in this area (37,38) (Figure 2).
Etiology of Infection  
Coagulase negative staphylococci (e.g., staphylococcus 
e p i d e r m i d i s ,  S t a p h y l o c o c c u s  l u g d u n e n s i s  a n d 
Staphylococcus capitis) are omnipresent cutaneous 
commensals that are implicated in complicated infectious 
endocarditis. They can colonize native heart valves and 
are the most common pathogens isolated in early PVE 
(19,21,39). It is not uncommon for coagulase negative 
staphylococci to cause hospital-acquired native valve 
endocarditis (40). In general, three blood culture series 
detect the presence of these pathogens in 96–98% of 
patients with bacteremia who have not yet started treatment 
with antibiotics (41,42). Blood culture does not need to 
be done at the febrile peak because the presence of the 
pathogen in the blood is not related to the extent of the 
fever. It is possible that patients in a compromised clinical 
condition have no pathogen growth from blood cultures 
delaying diagnosis (4). This situation is reported in up to 
10% of cases and it is linked: (I) to the early administration 
of antibiotics before blood cultures; (II) to the sustained 
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infection by slow-growing pathogens or fungi and (III) to 
particular conditions in which an alternative diagnosis of 
non-bacterial thrombotic endocarditis is can be made as in 
patients with advanced cancer (43).
Infection related due to Viridans streptococci vehicle 
by oro-pharyngeal transmission remains more common in 
low-income countries (44). Serial blood cultures can lead to 
the discovery of Streptococcus mutans, Streptococcus salivarius, 
Streptococcus anginosus, Streptococcus mitis and Streptococcus 
sanguinis. Of particular interest is the role played by group 
D streptococci (e.g., Gallolyticus Streptococcus, Streptococcus 
bovis) that are involved in the IE in patients with a coexisting 
colon tumor, which provides the portal circulation as a 
route of entry. The pathogens belonging to the group of 
Enterococci represent 10% of the overall cases (29,30).
Other forms of endocarditis are related to zoonotic 
infection as Coxiella burnetii, Brucella (cattle), Bartonella 
henselae (from cats) and Chlamydia psittaci (as parrots, 
pigeons). 
Infections caused by Gram-negative bacteria (e.g., 
Acinetobacter spp, Pseudomonas aeruginosa) and Legionella spp, 
Mycoplasma spp and Tropheryma whippelii can be of particular 
concern (45). Furthermore, fungal endocarditis, usually 
caused by Candida or Aspergillus, are very aggressive and 
often fatal because it occurs in the immunosuppressed 
patient or after cardiac surgery, mainly in the prosthetic 
valve recipients (46). 
A causative pathogen for IE can be identified in about 
two thirds of patients by additional microbiological 
tests (47). If the patient has negative cultures at 5 days, 
serological tests for Coxiella and bartonella are indicated 
and if these is also negative, the next step should involve 
testing for brucella, Mycoplasma, Legionella, and 
chlamydia (48). In the presence of an unrecognized 
infection, prolonged blood culture after 7 days does 
not provide further useful yields, even for the HACEK 
bacteria, which are typically slow-growing (48,49). After 
surgery the possibility of having samples the valve, can 
help in the microbiological diagnosis through the use 
of complementary molecular techniques as polymerase 
chain reaction for pathogen DNA (PCR) (50-52). These 
techniques are particularly useful in patients that received 
antibiotics, as bacterial DNA often persists even for non-
cultivable pathogens such as T whipplei (51,53). 
However, PCR carries the risk of a false positive result 
due to contamination of the sample. Clearly in this case 
PCR should not be used to guide the duration of therapy. 
New techniques combining PCR and mass spectrometry 
promise direct characterization of bacteria in peripheral 
blood or valvular tissue (51).
During the IE a very important factor is the host immune 
response where the macrophages play a key role (54). 
In the most fragile patients and in the presence of very 
aggressive pathogens infection can be spread beyond the 
valve annulus. The use of echocardiography plays a key role 
in the diagnosis and identification of anatomopathological 
complications resulting from the progression and 
expansion of the infection. Extension of the lesion inducing 
the formation of abscess, pseudoaneurysm, fistula, or 
atrioventricular block define a complex IE. Although 
transthoracic echocardiography (TTE) is sensitive (75%) 
and specific (more than 90%) for detection of a vegetation, 
transoesophageal echocardiography (TOE) is required for 
detection of complicated extensive lesion because it offers a 
sensitivity of more than 90% (55). The TOE colour doppler 
analysis can reveal a pseudoaneurysm, i.e. a perivalvular 
cavity that communicates with the cardiovascular lumen. 
Conversely, an abscess is a thickened, pus-filled perivalvular 
cavity that has no such communication. A progressive 
perivalvular infection can evolve into the formation of 
fistula whose pathoanatomical feature is usually an aorto-
cavitary aspect. The onset of this complication is burdened 
by a mortality rate greater than 40% even with surgery (56). 
For patients with persistent or relapsing infection or 
infection caused by aggressive or antibiotic-resistant 
microorganisms (e.g., lugdunensis, pseudomonas, fungi) 
there is an indication for emergency surgery (57) (Figure 2).
Risk of embolism
The risk of embolism with devastating complication 
occurs for a percentage of 25–50% of patients with IE (10). 
In the presence of left side endocarditis, the onset of a 
stroke is more common than infarction at level of the 
kidneys, spleen, limbs, mesenteric and coronary arteries. 
Furthermore, the localization of septic emboli in the 
context of the vascular structure can provoke a secondary 
infection related to the colonization of the “metastatic” 
vegetations. The inflammatory process that arises in 
the vascular wall is the cause of formation of a mycotic 
aneurysm. This lesion develops more frequently in the 
cerebral vessels and are visible on brain imaging in 3–5% 
of patients with IE, although in most cases they can remain 
clinically silent (10,58-60). The IE that are localized in 
right-sided of the heart are potentially at risk to determine 
lung embolism, or systemic embolism in patients 
Benedetto et al. Early surgery for IE
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presenting a patent foramen ovale. In a large percentage 
of patients emboli give a clinical manifestation in the 
first 2 weeks after the diagnosis and the risk decreases 
rapidly after the initiation of therapy with antibiotics 
(61,62). Vilacosta et al. (61) evaluated the risk of systemic 
embolization in 217 patients with left-sided IE who had 
initiated an adequate antibiotic treatment. In patients 
undergoing antibiotic therapy reduced rate embolic 
events was observed [12.9% vs. 87.1%; relative risk of new 
embolization (RR) 1.73; 95% CI, 1.2 to 2.93; P=0.05]. 
The majority of emboli (52%) affected the central nervous 
system, and 65% of the embolic events occurred during 
the first two weeks after initiation of antibiotic treatment. 
The authors showed that there was an increased risk of 
embolization parallel to vegetation size (RR 3.77, 95% CI 
from 0.97 to 12.57; P=0.07). In addition, both the presence 
of large (>10 mm) vegetation caused by staphylococcal 
Aureus pathogens (P=0.04) and the location on the mitral 
valve (P=0.03) had a higher incidence of embolism (61). 
In another report, 1,437 patients with IE were studied 
to determine the relationship between the initiation of 
antimicrobial therapy and the temporal incidence of 
stroke. During the study, the approximate incidence of 
stroke in patients receiving appropriate antimicrobial 
therapy was 4.82/1,000 patient days in the first week of 
therapy with a reduction to 1.71/1,000 patient days in the 
second week. Note that after one week of antimicrobial 
therapy, only 3.1% of the cohort had a stroke and reduced 
stroke rates was evident regardless of the type of valve or 
pathogen involved (62).
In patients who have experienced a stroke, surgery 
should not be postponed in cases with no coma and cerebral 
hemorrhage (class IIa, level B). In patients with neurological 
diagnosis of minor brain events, such as transient ischemic 
attack or silent cerebral embolism, the criterion is to 
recommend surgery without delay (class 1, level B) (5). 
Conversely, in patients who have experienced devastating 
neurological events such as intracranial hemorrhage and 
brain localization of septic emboli with hemorrhagic 
evolution intervention should be delayed for at least 1 
month. In this category of patients it is recommended to 
perform CT scans or MRI perfusion scan to evaluate the 
progression of the lesion according to the guidelines (class 
IIa, level B) (5). Okita et al. specific investigations revealed 
that early surgery (<7 days) demonstrated safety and efficacy 
in patients included in class I and IIa level B without 
preoperative haemorrhagic stroke (63). CT scans repeated 
immediately before surgery can rule out hemorrhagic 
evolution of cerebral infarction or the development of 
mycotic aneurysm (64) (Figure 2).
Clinical considerations
Over the past 20 years 7 RCT were published on antibiotic 
treatment (65-70), but only one RCT (26) investigated the 
comparison between medical therapy and early surgery 
within 48 hours. Thus, conclusive evidence to indicate 
which of these interventions is superior is missing.
In patients with IE the use of early surgery performed 
within 48 after diagnosis revealed a decrease in the rate of 
death from any causes as well as a reduction of the risk of 
systemic embolism (4,5,26,71,72). The concern related to 
the use of early surgery may be related to an increase in 
operative mortality and an increased risk of recurrence of IE. 
However, in patients who underwent emergency surgery we 
observed improvements in clinical outcomes were achieved 
without an increase in operative mortality or recurrence 
of infectious endocarditis (4,5,71-73). These results were 
comparable to those by Kang et al. (26). The mortality rate is 
related to the extension of infectious lesion and the etiology 
and the localization vegetation on the mitral valve leaflet 
(4,59). Particular attention should be given to the risk of 
embolization which has been reported to be particularly high 
in the first week before diagnosis (7) and affecting the central 
nervous system in up to 65% (1,2,74). 
Nonetheless, several propensity matched analyses 
showed contradictive results in terms of surgery morbidity 
and mortality (26,75,76). This might be related to the 
weight of embolic stroke and heart failure as determinants 
of long-term mortality. However, treatment allocation bias, 
underpowering and survivor bias affecting retrospective 
studies surely have played a role (26,75,77). 
In the sole RCT (26) the rate of embolism in patients 
who received early surgery was markedly reduced as 
compared to those who had conventional treatment. The 
rate of embolism in the medical treatment arm was similar 
to that reported in other prospective multicenter study (10) 
or RCT (68). 
We have reported that with a careful selection of patients 
could result in low in-hospital mortality and 6-months 
mortality (4,5,71,72). Poor prognostic factors, such as 
moderate to severe congestive heart failure, altered mental 
status and staphylococcal infection lead to increased 
mortality, substantially comparable to that of other studies 
(26,78-83). In our experience, patients with vegetations 
>15 mm at high risk of mobility and located on the mitral 
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valve, derive a considerable benefit from emergency surgical 
treatment, as confirmed elsewhere (4,5,37,38,71,72).
Emergency surgical treatment within 48 hours can be 
offered to patients who experienced an infection with severe 
anatomic-pathological injuries with development of abscess, 
extracardiac fistula or aortic root involvement. In this case 
the risk of mortality is higher considering the technical 
demand and the preoperative patient’s conditions. 
In these patients an extensive and radical surgery is 
necessary and homografts, conventional mechanical valves 
or xenografts are used in similar complex endocarditis. In a 
study reported by Harvard group (79) the abscess formation 
had an incidence of 43.09% (n=131), which is higher 
than the mean frequency (25–30%) reported by other 
international studies, indicating the severity of the disease 
treated in this cohort. In any case out of 131 patients with 
abscess formation 40.5% received a mechanical valve and 
while 29.5% were treated using xenograft. Selection of the 
type of graft to be used should be driven by the resistance 
to infection, as re-do surgery in case of reinfection is 
particularly challenging and burdened by augmented risk. In 
particular, reinfection of synthetic prostheses or prosthetic 
materials is even more daunting and technically demanding 
than in case of re-endocarditis on a previous homograft. In 
this context, evidences on safety and durability of homograft 
surgery has been widely reported. Already in 2001, Moon 
et al. (84) revealed a reinfection rate of 2% at 10 years with 
the majority of infection relapse following aortic valve 
endocarditis surgery and occurring within the first year. 
More recently Flameng et al. (85) showed a low recurrence 
of endocarditis in patients who received a homograft to 
treat complex IE. Excellent results are reported in the large 
series of Arabkhani et al. (86) with a rate of intraoperative 
mortality of 5.5% and durability up to 27 years.
Although some reports, as the current from Harvard (79), 
praised the long-term outcomes of mechanical valves, 
it cannot be neglected that these prostheses are bond 
to a life-long anticoagulation which carries significant 
risks. Additionally, the population normally afflicted by 
endocarditis is relatively young and willing to conduct 
an active life and oral anticoagulation means a significant 
impairment in patient’s quality of life. Also, in case of female 
patients, possibility of pregnancy is excluded. Moreover, if 
we take into consideration the final objective of endocarditis 
treatment, there is a significant lower infection recurrence 
using homografts (87,88) even in the context of previous 
prosthetic valve (89).
We reported the use of cryopreserved homograft for 
AVR in 210 patients (72) and one half of the patients had 
endocarditis, 21% of these had an abscess formation. In 
our series the use of a cryopreserved aortic homograft was 
associated with no early reinfection and only 4 late relapses 
of endocarditis. In presence of extensive infection, in young 
patients with complex aorto-mitral endocarditis or aortic 
root involvement we used a living pulmonary autograft 
(90-95) or a double homograft valve replacement (4,5,71). 
In our experimental studies from a mechanical point of 
view, the use of a PA has shown efficacy compared to the 
use of dacron (96,97).
We believe that in case of extensive infection performing 
a quicker operation using a prosthetic valve with or without 
a dacron graft provides a very unstable situation with 
high potential for infection recurrence (72). Decision on 
surgery is always deriving from a balance between the risk 
of the procedure and the benefit achievable. Therefore, 
considering the significant risk during endocarditis surgery 
and the even higher risk represented by a redo-operation 
for re-infection, we believe that the option to undergo a 
minimal operation with known potential for re-infection 
should be discouraged (Figure 3).
Conclusions
The indication for early surgery in IE has not yet been 
appropriately defined and it differs significantly between the 
European (5) and US guidelines (13) fueling the confusion 
regarding the relative priority of surgical or medical 
management. The ESC guidelines (5) individuates three 
moments for the surgical indication. Emergency surgery 
which is performed within 24 hours, urgent surgery which is 
recommended within a few days and elective surgery which 
is performed after 1–2 weeks of antibiotic therapy. Urgent 
surgery is recommended for most cases of IE. Instead, the 
AHA’s guidelines (13) define early surgery as “during the 
initial hospitalization and before completion of a full course 
of antibiotics.” We believe that in the presence of a clear 
diagnosis of IE and when an indication for surgery has been 
established, there are no proven benefits in delaying surgery 
(4,26). The choice to perform an intervention for IE in 
the early hours or with a delay of 48 hours depends on the 
way the heart team works in the shared decision-making 
process (4). There is evidence that has shown very low 
mortality in centers of excellence with high level experience 
in the management of complex patients and a RCT (26) 
has supported the role of early surgery. However, further 
evidences are needed to inform guidelines on the surgical 
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Figure 3 Decision Tree for Distinguishing Early Surgery in HVE. LV, left ventricle; LA, left atrium; ACC/AHA, American College of 
Cardiology/American Heart association; ESC, European Society of Cardiologists; HVE, heart valve endocarditis; LVEF, left ventricular 
ejection fraction; TIA, transient Ischemic attack. 




Provenance and Peer Review: This article was commissioned 
by the Guest Editors (Drs. Francesco Nappi, Christos 
Mihos, and Cristiano Spadaccio) for the series “Infective 
Endocarditis in the 21st Century” published in Annals of 
Translational Medicine. The article was sent for external peer 
review organized by the Guest Editors and the editorial 
office.
Reporting Checklist: The authors have completed the 
Narrative Review reporting checklist. Available at http://
dx.doi.org/10.21037/atm-20-3880
Conflicts of Interest: All authors have completed the 
ICMJE uniform disclosure form (available at http://
dx.doi.org/10.21037/atm-20-3880). The series “Infective 
Endocarditis in the 21st Century” was commissioned by 
the editorial office without any funding or sponsorship. FN 
served as the unpaid Guest Editor of the series and serves as 
an unpaid editorial board member of Annals of Translational 
Medicine from Feb 2019 to Jan 2021. CS served as the 
unpaid Guest Editor of the series. The other authors have 
no other conflicts of interest to declare. 
Ethical Statement: The authors are accountable for all 
aspects of the work in ensuring that questions related 
to the accuracy or integrity of any part of the work are 
Annals of Translational Medicine, Vol 8, No 23 December 2020 Page 9 of 12
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2020;8(23):1626 | http://dx.doi.org/10.21037/atm-20-3880
appropriately investigated and resolved. 
Open Access Statement: This is an Open Access article 
distributed in accordance with the Creative Commons 
Attribution-NonCommercial-NoDerivs 4.0 International 
License (CC BY-NC-ND 4.0), which permits the non-
commercial replication and distribution of the article with 
the strict proviso that no changes or edits are made and the 
original work is properly cited (including links to both the 
formal publication through the relevant DOI and the license). 
See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
1. Mylonakis E, Calderwood SB. Infective endocarditis in 
adults. N Engl J Med 2001;345:1318-30. 
2. Baddour LM, Wilson WR, Bayer AS, et al. Infective 
endocarditis: diagnosis, antimicrobial therapy, and 
management or complications: a statement for healthcare 
professionals from the Committee on Rheumatic 
Fever, Endocarditis, and Kawasaki Disease, Council on 
Cardiovascular Disease in the Young, and the Councils on 
Clinical Cardiology, Stroke, and Cardiovascular Surgery 
and Anesthesia, American Heart Association: endorsed by 
the Infectious Diseases Society of America. Circulation 
2005;111:e394-434. 
3. Nappi F, Spadaccio C, Dreyfus J, et al. Mitral endocarditis: 
A new management framework. J Thorac Cardiovasc Surg 
2018;156:1486-95.e4. 
4. Nappi F, Spadaccio C, Acar C. Use of allogeneic tissue to 
treat infective valvular disease: Has everything been said? J 
Thorac Cardiovasc Surg 2017;153:824-8. 
5. Habib G, Hoen B, Tornos P, et al. Guidelines on 
the prevention, diagnosis, and treatment of infective 
endocarditis (new version 2009): the Task Force on 
the Prevention, Diagnosis, and Treatment of Infective 
Endocarditis of the European Society of Cardiology (ESC). 
Eur Heart J 2009;30:2369-413.
6. Prendergast BD, Tornos P. Surgery for infective endocarditis: 
who and when? Circulation 2010;121:1141-52.
7. Cahill TJ, Baddour LM, Habib G, et al. Challenges in 
Infective Endocarditis. J Am Coll Cardiol 2017;69:325-44. 
8. Cahill TJ, Prendergast BD. Infective endocarditis. Lancet 
2016;387:882-93.
9. Moreillon P, Que YA. Infective endocarditis. Lancet 
2004;363:139-49.
10. Thuny F, Di Salvo G, Belliard O, et al. Risk of embolism 
and death in infective endocarditis: prognostic value 
of echocardiography: a prospective multicenter study. 
Circulation 2005;112:e175.
11. Tornos P, Iung B, Permanyer-Miralda G, et al. Infective 
endocarditis in Europe: lessons from the Euro heart 
survey. Heart 2005;91:571-5.
12. Delahaye F. Is early surgery beneficial in infective 
endocarditis? A systematic review. Arch Cardiovasc Dis 
2011;104:35-44.
13. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/
ACC Focused Update of the 2014 AHA/ACC Guideline 
for the Management of Patients With Valvular Heart 
Disease: A Report of the American College of Cardiology/
American Heart Association Task Force on Clinical 
Practice Guidelines. Circulation 2017;135:e1159-95.
14. Agnihotri AK, McGiffin DC, Galbraith AJ, et al. The 
prevalence of infective endocarditis after aortic valve 
replacement. J Thorac Cardiovasc Surg 1995;110:1708-20.
15. Calderwood SB, Swinski LA, Waternaux CM, et al. 
Risk factors for the development of prosthetic valve 
endocarditis. Circulation 1985;72:31-7.
16. Arvay A, Lengyel M. Incidence and risk factors of 
prosthetic valve endocarditis. Eur J Cardiothorac Surg 
1988;2:340-6.
17. Wang A, Athan E, Pappas PA, et al. Contemporary clinical 
profile and outcome of prosthetic valve endocarditis. 
JAMA 2007;297:1354-61.
18. Attaran S, Chukwuemeka A, Punjabi PP, et al. Do all 
patients with prosthetic valve endocarditis need surgery? 
Interact Cardiovasc Thorac Surg 2012;15:1057-61.
19. Alonso-Valle H, Fariñas-Alvarez C, García-Palomo JD, 
et al. Clinical course and predictors of death in prosthetic 
valve endocarditis over a 20-year period. J Thorac 
Cardiovasc Surg 2010;139:887-93.
20. Habib G, Tribouilloy C, Thuny F, et al. Prosthetic valve 
endocarditis: who needs surgery? A multicentre study of 
104 cases. Heart 2005;91:954-9.
21. López J, Revilla A, Vilacosta I, et al. Definition, clinical 
profile, microbiological spectrum, and prognostic factors 
of early-onset prosthetic valve. Eur Heart J 2007;28:760-5.
22. Chirouze C, Cabell CH, Fowler VG Jr, et al. International 
Collaboration on Endocarditis Study Group. Prognostic 
factors in 61 cases of Staphylococcus aureus prosthetic 
valve infective endocarditis from the International 
Collaboration on Endocarditis merged database. Clin 
Infect Dis 2004;38:1323-7.
23. Tornos P, Almirante B, Olona M, et al. Clinical 
outcome and long-term prognosis of late prosthetic 
valve endocarditis: a 20-year experience. Clin Infect Dis 
Benedetto et al. Early surgery for IE
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2020;8(23):1626 | http://dx.doi.org/10.21037/atm-20-3880
Page 10 of 12
1997;24:381-6.
24. Truninger K, Attenhofer Jost CH, Seifert B, et al. 
Long term follow up of prosthetic valve endocarditis: 
what characteristics identify patients who were treated 
successfully with antibiotics alone? Heart 1999;82:714-20.
25. Rekik S, Trabelsi I, Maaloul I, et al. Short- and long-term 
outcomes of surgery for active infective endocarditis: a 
Tunisian experience. Interact Cardiovasc Thorac Surg 
2009;9:241-5.
26. Kang DH, Kim YJ, Kim SH, et al. Early surgery versus 
conventional treatment for infective endocarditis. N Engl 
J Med 2012;366:2466-73.
27. Olmos C, Vilacosta I, Fernandez C, et al. Contemporary 
epidemiology and prognosis of septic shock in infective 
endocarditis. Eur Heart J 2013;34:1999-2006.
28. Werdan K, Dietz S, Löffler B, et al. Mechanisms of 
infective endocarditis: pathogen-host interaction and risk 
states. Nat Rev Cardiol 2014;11:35-50.
29. Murdoch DR, Corey GR, Hoen B, et al. Clinical 
presentation, etiology, and outcome of infective 
endocarditis in the 21st century: the International 
Collaboration on Endocarditis-Prospective Cohort Study. 
Arch Intern Med 2009;169:463-73.
30. Selton-Suty C, Célard M, Le Moing V, et al, and the 
AEPEI Study Group. Preeminence of Staphylococcus 
aureus in infective endocarditis: a 1-year population-based 
survey. Clin Infect Dis 2012;54:1230-39.
31. Fowler VG Jr, Li J, Corey GR, et al. Role of 
echocardiography in evaluation of patients with 
Staphylococcus aureus bacteremia: experience in 103 
patients. J Am Coll Cardiol 1997;30:1072-78.
32. Joseph JP, Meddows TR, Webster DP, et al. Prioritizing 
echocardiography in Staphylococcus aureus bacteraemia. J 
Antimicrob Chemother 2013;68:444-49.
33. Durante-Mangoni E, Bradley S, Selton-Suty C, et al. 
Current features of infective endocarditis in elderly 
patients: results of the International Collaboration on 
Endocarditis Prospective Cohort Study. Arch Intern Med 
2008;168:2095-103.
34. Richardson JV, Karp RB, Kirklin JW, et al. Treatment 
of infective endocarditis: a 10-year comparative analysis. 
Circulation 1978;58:589-97.
35. Croft CH, Woodward W, Elliott A, et al. Analysis of 
surgical versus medical therapy in active complicated 
native valve infective endocarditis. Am J Cardiol 
1983;51:1650-55.
36. Gálvez-Acebal J, Almendro-Delia M, Ruiz J, et al. 
Study Group for Cardiovascular Infections, part of the 
Andalusian Society of Infectious Diseases. Influence of 
early surgical treatment on the prognosis of left-sided 
infective endocarditis: a multicenter cohort study. Mayo 
Clin Proc 2014;89:1397-405. 
37. Nappi F, Spadaccio C. Simplest solutions are not always 
the cleverest: Can we stitch in an infected annulus? Should 
we rethink the current guidelines? J Thorac Cardiovasc 
Surg 2017;154:1899-900. 
38. Nappi F, Spadaccio C. Keep fumbling around in the 
dark when it comes to infective endocarditis, or produce 
new, reliable data to redesign the guidelines? J Thorac 
Cardiovasc Surg 2018;155:75-6.
39. Becker K, Heilmann C, Peters G. Coagulase-negative 
staphylococci. Clin Microbiol Rev 2014;27:870-926.
40. Chu VH, Woods CW, Miro JM, et al. Emergence of 
coagulase-negative staphylococci as a cause of native valve 
endocarditis. Clin Infect Dis 2008;46:232-42.
41. Lee A, Mirrett S, Reller LB, et al. Detection of 
bloodstream infections in adults: how many blood cultures 
are needed? J Clin Microbiol 2007;45:3546-8.
42. Cockerill FR 3rd, Wilson JW, Vetter EA, et al. Optimal 
testing parameters for blood cultures. Clin Infect Dis 
2004;38:1724-30.
43. Asopa S, Patel A, Khan OA, et al. Non-bacterial 
thrombotic endocarditis. Eur J Cardiothorac Surg 
2007;32:696-701.
44. Yew HS, Murdoch DR. Global trends in infective endocarditis 
epidemiology. Curr Infect Dis Rep 2012;14:367-72.
45. Brouqui P, Raoult D. Endocarditis due to rare and 
fastidious bacteria. Clin Microbiol Rev 2001;14:177-207.
46. Baddley JW, Benjamin DK Jr, Patel M, et al. Candida 
infective endocarditis. Eur J Clin Microbiol Infect Dis 
2008;27:519-29.
47. Fournier PE, Thuny F, Richet H, et al. Comprehensive 
diagnostic strategy for blood culture-negative endocarditis: 
a prospective study of 819 new cases. Clin Infect Dis 
2010;51:131-40.
48. Gould FK, Denning DW, Elliott TSJ, et al. Guidelines for 
the diagnosis and antibiotic treatment of endocarditis in 
adults: a report of the Working Party of the British Society 
for Antimicrobial Chemotherapy. J Antimicrob Chemother 
2012;67:269-89.
49. Petti CA, Bhally HS, Weinstein MP, et al. Utility of 
extended blood culture incubation for isolation of 
Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, 
and Kingella organisms: a retrospective multicenter 
evaluation. J Clin Microbiol 2006;44:257-59.
50. Goldenberger D, Künzli A, Vogt P, et al. Molecular 
Annals of Translational Medicine, Vol 8, No 23 December 2020 Page 11 of 12
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2020;8(23):1626 | http://dx.doi.org/10.21037/atm-20-3880
diagnosis of bacterial endocarditis by broad-range PCR 
amplification and direct sequencing. J Clin Microbiol 
1997;35:2733-9.
51. Vondracek M, Sartipy U, Aufwerber E, et al. 16S rDNA 
sequencing of valve tissue improves microbiological 
diagnosis in surgically treated patients with infective 
endocarditis. J Infect 2011;62:472-8.
52. Bosshard PP, Kronenberg A, Zbinden R, et al. Etiologic 
diagnosis of infective endocarditis by broad-range 
polymerase chain reaction: a 3-year experience. Clin Infect 
Dis 2003;37:167-72.
53. Geissdörfer W, Moos V, Moter A, et al. High frequency of 
Tropheryma whipplei in culture-negative endocarditis. J 
Clin Microbiol 2012;50:216-22.
54. Brinkman CL, Vergidis P, Uhl JR, et al. PCR-electrospray 
ionization mass spectrometry for direct detection of 
pathogens and antimicrobial resistance from heart valves 
in patients with infective endocarditis. J Clin Microbiol 
2013;51:2040-6.
55. Habib G, Badano L, Tribouilloy C, et al. 
Recommendations for the practice of echocardiography in 
infective endocarditis. Eur J Echocardiogr 2010;11:202-19.
56. Anguera I, Miro JM, Vilacosta I, et al. Aorto-cavitary 
fistulous tract formation in infective endocarditis: clinical 
and echocardiographic features of 76 cases and risk factors 
for mortality. Eur Heart J 2005;26:288-97
57. Malhotra A, Rayner J, Williams TM, et al. Infective 
endocarditis: therapeutic options and indications for 
surgery. Curr Cardiol Rep 2014;16:464-9.
58. Peters PJ, Harrison T, Lennox JL. A dangerous dilemma: 
management of infectious intracranial aneurysms 
complicating endocarditis. Lancet Infect Dis 2006;6:742-8.
59. Duval X, Iung B, Klein I, et al. Effect of early cerebral 
magnetic resonance imaging on clinical decisions in 
infective endocarditis: a prospective study. Ann Intern Med 
2010;152:497-504.
60. Hess A, Klein I, Iung B, et al. Brain MRI findings in 
neurologically asymptomatic patients with infective 
endocarditis. AJNR Am J Neuroradiol 2013;34:1579-84.
61. Vilacosta I, Graupner C, San Román JA, et al. Risk of 
embolization after institution of antibiotic therapy for 
infective endocarditis. J Am Coll Cardiol 2002;39:1489-95.
62. Dickerman SA, Abrutyn E, Barsic B, et al. The relationship 
between the initiation of antimicrobial therapy and the 
incidence of stroke in infective endocarditis: an analysis 
from the ICE Prospective Cohort Study (ICE-PCS). Am 
Heart J 2007;154:1086-94.
63. Okita Y, Minakata K, Yasuno S, et al. Optimal timing 
of surgery for active infective endocarditis with cerebral 
complications: a Japanese multicentre study. Eur J 
Cardiothorac Surg 2016;50:374-82.
64. Hui FK, Bain M, Obuchowski NA, et al. Mycotic 
aneurysm detection rates with cerebral angiography in 
patients with infective endocarditis. J Neurointerv Surg 
2015;7:449-52.
65. Ribera E, Gómez-Jimenez J, Cortes E, et al. Effectiveness 
of cloxacillin with and without gentamicin in short-
term therapy for right-sided Staphylococcus aureus 
endocarditis. A randomized, controlled trial. Ann Intern 
Med 1996;125:969-74.
66. Fowler VG Jr., Boucher HW, Corey GR, et al. 
Daptomycin versus standard therapy for bacteremia and 
endocarditis caused by Staphylococcus aureus. N Engl J 
Med 2006;355:653-65.
67. Heldman AW, Hartert TV, Ray SC, et al. Oral antibiotic 
treatment of right-sided staphylococcal endocarditis in 
injection drug users: prospective randomized comparison 
with parenteral therapy. Am J Med 1996;101:68-76.
68. Chan KL, Dumesnil JG, Cujec B, et al. A randomized trial 
of aspirin on the risk of embolic events in patients with 
infective endocarditis. J Am Coll Cardiol 2003;42:775-80.
69. Fortún J, Navas E, Martínez-Beltrán J, et al. Short-course 
therapy for right-side endocarditis due to Staphylococcus 
aureus in drug abusers: cloxacillin versus glycopeptides 
in combination with gentamicin. Clin Infect Dis 
2001;33:120-5.
70. Sexton DJ, Tenenbaum MJ, Wilson WR, et al. Ceftriaxone 
once daily for four weeks compared with ceftriaxone plus 
gentamicin once daily for two weeks for treatment of 
endocarditis due to penicillin susceptible streptococci. 
Endocarditis Treatment Consortium Group. Clin Infect 
Dis 1998;27:1470-4.
71. Olivito S, Lalande S, Nappi F, et al. Structural 
deterioration of the cryopreserved mitral homograft valve. 
J Thorac Cardiovasc Surg 2012;144:313-20.e1.
72. Nappi F, Nenna A, Petitti T, et al. Long-term outcome 
of cryopreserved allograft for aortic valve replacement. J 
Thorac Cardiovasc Surg 2018;156:1357-65.e6.
73. Steckelberg JM, Murphy JG, Ballard D, et al. Emboli 
in infective endocarditis: the prognostic value of 
echocardiography. Ann Intern Med 1991;114:635-40.
74. Habib G. Management of infective endocarditis. Heart 
2006;92:124-30.
75. Vikram HR, Buenconsejo J, Hasbun R, et al. Impact 
of valve surgery on 6-month mortality in adults with 
complicated, left-sided native valve endocarditis: a 
Benedetto et al. Early surgery for IE
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2020;8(23):1626 | http://dx.doi.org/10.21037/atm-20-3880
Page 12 of 12
propensity analysis. JAMA 2003;290:3207-14.
76. Lalani T, Cabell CH, Benjamin DK, et al. Analysis of 
the impact of early surgery on in-hospital mortality of 
native valve endocarditis: use of propensity score and 
instrumental variable methods to adjust for treatment-
selection bias. Circulation 2010;121:1005-13.
77. Thuny F, Beurtheret S, Mancini J, et al. The timing of 
surgery influences mortality and morbidity in adults with 
severe complicated infective endocarditis: a propensity 
analysis. Eur Heart J 2011;32:2027-33.
78. David TE, Gavra G, Feindel CM, et al. Surgical treatment 
of active infective endocarditis: a continued challenge. J 
Thorac Cardiovasc Surg 2007;133:144-9.
79. Kim JB, Ejiofor JI, Yammine M, et al. Are homografts 
superior to conventional prosthetic valves in the setting of 
infective endocarditis involving the aortic valve? J Thorac 
Cardiovasc Surg 2016;151:1239-48.e12482.
80. Fukushima S, Tesar PJ, Pearse B, et al. Long-term 
clinical outcomes after aortic valve replacement using 
cryopreserved aortic allograft. J Thorac Cardiovasc Surg 
2014;148:65-72.e2.
81. Hussain ST, Shrestha NK, Gordon SM, et al. Residual 
patient, anatomic, and surgical obstacles in treating active 
left-sided infective endocarditis. J Thorac Cardiovasc Surg 
2014;148:981-8.e4.
82. Grubitzsch H, Schaefer A, Melzer C, et al. Outcome after 
surgery for prosthetic valve endocarditis and the impact 
of preoperative treatment. J Thorac Cardiovasc Surg 
2014;148:2052-9.
83. Manne MB, Shrestha NK, Lytle BW, et al. Outcomes after 
surgical treatment of native and prosthetic valve infective 
endocarditis. Ann Thorac Surg 2012;93:489-93.
84. Moon MR, Miller DC, Moore KA, et al. Treatment of 
endocarditis with valve replacement: the question of 
tissue versus mechanical prosthesis. Ann Thorac Surg 
2001;71:1164-71.
85. Flameng W, Daenen W, Jashari R, et al. Durability of 
homografts used to treat complex aortic valve endocarditis. 
Ann Thorac Surg 2015;99:1234-8.
86. Arabkhani B, Bekkers JA, Andrinopoulou ER, et al. 
Allografts in aortic position: Insights from a 27-year, 
single-center prospective study. J Thorac Cardiovasc Surg 
2016;152:1572-79.e3.
87. Musci M, Weng Y, Hubler M, et al. Homograft aortic 
root replacement in native or prosthetic active infective 
endocarditis: twenty-year single-center experience. J 
Thorac Cardiovasc Surg 2010;139:665-73.
88. Yankah AC, Klose H, Petzina R, et al. Surgical management 
of acute aortic root endocarditis with viable homograft:13-
year. Eur J Cardiothorac Surg 2002;21:260-7.
89. Perrotta S, Jeppsson A, Frojd V, et al. Surgical Treatment 
of Aortic Prosthetic Valve Endocarditis: A 20-Year Single-
Center Experience. Ann Thorac Surg 2016;101:1426-32.
90. Nappi F, Spadaccio C, Chello M, et al. The Ross 
procedure: Underuse or under-comprehension? J Thorac 
Cardiovasc Surg 2015;149:1463-4.
91. Nappi F, Nenna A, Larobina D, et al. Simulating the ideal 
geometrical and biomechanical parameters of the pulmonary 
autograft to prevent failure in the Ross operation. Interact 
Cardiovasc Thorac Surg 2018;27:269-76.
92. Nappi F, Avtaar Singh SS, Spadaccio C, et al. Ross 
operation 23 years after surgery: It should not be a 
"forgotten" option. J Card Surg 2020;35:952-6.
93. Nappi F, Spadaccio C, Al-Attar N, et al. The Ross 
procedure at the crossroads: lessons from biology: is Dr 
Ross's dream concluded? Int J Cardiol 2015;178:37-9
94. Spadaccio C, Montagnani S, Acar C, et al. Introducing 
bioresorbable scaffolds into the show. A potential adjunct 
to resuscitate Ross procedure. Int J Cardiol 2015;190:50-2.
95. Nappi F, Fraldi M, Spadaccio C, et al. Biomechanics 
drive histological wall remodeling of neoaortic root: A 
mathematical model to study the expression levels of ki 67, 
metalloprotease, and apoptosis transition. J Biomed Mater 
Res A 2016;104:2785-93.
96. Nappi F, Carotenuto AR, Cutolo A et al. Compliance 
mismatch and compressive wall stresses drive 
anomalous remodelling of pulmonary trunks reinforced 
with Dacron grafts. J Mech Behav Biomed Mater 
2016;63:287-302.
97. Spadaccio C, Nappi F, Al-Attar N, et al. Old Myths, New 
Concerns: the Long-Term Effects of Ascending Aorta 
Replacement with Dacron Grafts. Not All That Glitters Is 
Gold. J Cardiovasc Transl Res 2016;9:334-42.
Cite this article as: Benedetto U, Spadaccio C, Gentile F, 
Moon MR, Nappi F. A narrative review of early surgery versus 
conventional treatment for infective endocarditis: do we have 
an answer? Ann Transl Med 2020;8(23):1626. doi: 10.21037/atm-
20-3880
